Closing up 42% at the end of the session, is it still too early to say that Junshengtai Pharmaceutical-B (02511) broke out of the trough?

With high investment in R&D, capital consumption will also increase. Whether the current cash can support the commercialization of Junshengtai's core products is still unknown.

Zhitong FinanceMay 8 04:39 ET

君聖泰醫藥-B：2023年報

Futu NewsApr 26 08:03 ET · Announcements

Changes in Hong Kong stocks | Junshengtai Pharmaceutical-B (02511) once rose more than 42% and previously announced the completion of the phase IIb clinical trial of HTD1801 to enroll patients

Junshengtai Pharmaceutical-B (02511) once rose by more than 42%. As of press release, it rose 23.49% to HK$5.31, with a turnover of HK$12.3888 million.

Zhitong FinanceApr 15 02:57 ET

HighTide Therapeutics Completes Patient Enrolment for Phase II Trial of Metabolic Modulator

HighTide Therapeutics (HKG:2511) has completed patient enrollment for the Phase II-b clinical trial of HTD1801, a gut-liver anti-inflammatory metabolic modulator, a Wednesday filing on the Hong Kong b

MT NewswiresApr 3 07:26 ET

Junshengtai Pharmaceutical-B (02511.HK): HTD1801 clinical trial to treat metabolic steatohepatitis (MASH) phase IIb completed patient enrollment

Gelonghui, April 3 | Junshengtai Pharmaceutical-B (02511.HK) announced that the Phase IIb clinical trial of the enterohepatic anti-inflammatory and metabolic regulator HTD1801 (Xiongdeoxycholic Berberberis), developed independently by the company, has enrolled patients. The trial targets patients with metabolic fatty hepatosis (MASH for short) with type 2 diabetes (T2DM) or pre-diabetes. This trial (Centricity study) is a randomized, double-blind, placebo-controlled global multicenter phase IIb clinical trial aimed at evaluating HTD1801 in

Gelonghui FinanceApr 3 05:59 ET

Junshengtai Pharmaceutical-B (02511) released annual results, R&D costs of 312 million yuan, an increase of 70.6% over the previous year

Junshengtai Pharmaceutical-B (02511) announced 2023 results, other revenue and revenue of 34.2 million yuan (people...

Zhitong FinanceMar 27 07:00 ET